RxDoctor Payments Data

Meena Shah, MD

Cardiovascular Disease · Prince Frederick, MDNPI 1669507877

Payments from drug & device makers

$1,863in general payments, 2019–2025

Across 94 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$294
  • Abbott$177
  • AstraZeneca$143
  • Nestle Healthcare Nutrition Inc.$94
  • Vifor Pharma, Inc.$86
  • Novartis$86
  • plus $982 from 25 others

What the payments were for

  • Food & beverage$1,863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,863 in reported general payments places this provider in the 50th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$563,887
Medicare patients
981
Services billed
7,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$322,142
XareltoRivaroxaban134$159,419
EntrestoSacubitril/Valsartan62$94,028
Repatha SureclickEvolocumab58$45,879
BrilintaTicagrelor12$11,590
Metoprolol Succinate439$8,234
Ezetimibe169$6,418
Rosuvastatin Calcium277$6,075
Atorvastatin Calcium423$5,165
Carvedilol300$2,853
Amlodipine Besylate323$2,596
Candesartan Cilexetil16$2,066
Amiodarone Hcl51$2,036
Losartan Potassium159$1,758
Nebivolol Hcl15$1,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$322,142239 claims
Johnson & JohnsonXarelto$64$159,419134 claims
NovartisEntresto$86$94,02862 claims
AstraZenecaBrilinta$143$11,59012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Prince Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →